If your patients are considering hormonal treatment they can also register to receive materials that explain in detail the risk for breast cancer recurrence and how hormonal treatment works. This information will help your patients during your discussions about treatment options.
The In Your Corner™ patient support program from AstraZeneca Pharmaceuticals LP was created with the help of oncology health care professionals and women who have had breast cancer.
When your patients enroll in the program, they will receive a series of mailings that will help them adjust to the period following initial cancer treatment; stay connected with a supportive community through monthly mailings; and receive guidance along their path from learning about their disease to focusing on everyday wellness.
If your patients are considering hormonal treatment they can also register to receive materials that explain in detail the risk for breast cancer recurrence and how hormonal treatment works. This information will help your patients during your discussions about treatment options. In addition, you can register for the In Your Corner™ patient support program, so you'll know all about the resources your patients will receive. For more information, you can click the link below.
In Your Corner™ patient support program registration
Finally, you can call the AstraZeneca Cancer Support Network 1-866-99-AZCSN (1-866-992-9276) if you have additional questions about In Your Corner, or questions on reimbursement issues, the AstraZeneca Foundation Patient Assistance Program, or Visions of Hope™ - a traveling, interactive, educational exhibit that appears at various Susan G. Komen Race for the Cure® events. The exhibit provides visitors, including breast cancer survivors and their families, with information related to breast cancer, detection, and treatment options.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More